Previous 10 | Next 10 |
2023-11-29 07:21:25 ET Summary The EU recommends Anavex proceed with a full approval application for Alzheimer's drug Blarcamesine based on full Phase 2b/3 trial data. The U.S. FDA may grant accelerated approval to Anavex's Blarcamesine based on biomarker data alone. Blarcamesine ...
2023-11-27 20:52:36 ET Summary ANAVEX2-73 Safety Follow-Up: Extended safety follow-up for Rett syndrome raises concerns but shows commitment to patient safety and scientific rigor. Financial Health: Anavex demonstrates robust short-term liquidity; however, increasing accumulated d...
2023-11-27 12:10:46 ET More on Anavex Life Sciences Anavex Life Sciences Corp. (AVXL) Q4 2023 Earnings Call Transcript Anavex Alzheimer's And Parkinson's Drug Underappreciated By Investors Anavex: The September Data Anavex gains as EU filing for Alzheimer...
2023-11-27 09:52:06 ET Anavex Life Sciences Corp. (AVXL) Q4 2023 Earnings Call Transcript November 27, 2023 08:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conferen...
2023-11-27 08:02:06 ET More on Anavex Life Sciences Anavex Alzheimer's And Parkinson's Drug Underappreciated By Investors Anavex: The September Data Anavex: Additional P2b/3 Alzheimer's Trial Data Raises Additional Questions Anavex gains as EU filing for Alzh...
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape...
Nippon Paint Holdings Co. Ltd. (NPCPF) is expected to report for Q3 2023 SMC Corporation ADR (SMCAY) is expected to report for Q2 2024 Arcimoto Inc. (FUV) is expected to report for Q3 2023 Ever-Glory International Group Inc. (EVKG) is expected to report for quarter end 2023-09-30 ...
Anavex Life Sciences Corp. (AVXL) is expected to report $-0.16 for Q4 2023
2023-11-26 08:24:18 ET AVXL , BMA , CRNC , ITRN , TIGR For Seeking Alpha's full earnings season calendar, click here . For further details see: Notable earnings before Monday's open
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...